Corcept Therapeutics (CORT) Finished Goods (2012 - 2026)

Corcept Therapeutics has disclosed Finished Goods across 15 years of filings, most recently posting $14.7 million for Q1 2026.

• Finished Goods for Q1 2026 came in at $14.7 million, up 72.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.7 million (up 72.88% YoY), and the FY2025 annual result was $9.4 million, up 14.7% from the prior year.
• Finished Goods came in at $14.7 million for Q1 2026 at Corcept Therapeutics, up from $9.4 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $14.7 million in Q1 2026 to a low of $5.5 million in Q1 2022.
• The 5-year median for Finished Goods is $8.1 million (2023), against an average of $8.2 million.
• Across the five-year window, Finished Goods retreated 19.47% in 2025 and jumped 72.88% in 2026, its largest moves.
• Corcept Therapeutics' Finished Goods stood at $9.2 million in 2022, then decreased by 15.9% to $7.7 million in 2023, then advanced by 6.01% to $8.2 million in 2024, then grew by 14.7% to $9.4 million in 2025, then surged by 56.11% to $14.7 million in 2026.
• The last three Finished Goods figures came in at $14.7 million (Q1 2026), $9.4 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.